Search

Bezafibrate (BZF) is a drug that reduces cholesterol and triglyceride levels in the blood. Research indicates that BZF, through activation of PPAR receptors, regulates the expression of genes involved in lipid homeostasis, inflammation, cell differentiation, and proliferation. This study investigated the in vitro and in vivo effects of BZF on activated hepatic stellate cells (HSCs) and on carbon tetrachloride-induced liver fibrosis in mice. After 72 h of treatment in vitro, BZF decreased cell proliferation, reversed the phenotype, decreased cell contraction, and induced autophagy. In addition, BZF promoted a protective effect on tetrachloride-induced liver fibrosis in mice, through antifibrotic actions. These findings suggest that BZF may have a potential antifibrotic effect, which could emerge as a possible new therapy for the treatment of liver fibrosis., Competing Interests: Declaration of competing interest The authors affirm that there are no conflicts of interest. They have all reviewed and approved the manuscript for submission., (Copyright © 2025 Elsevier Ltd. All rights reserved.)

Background: Cystic fibrosis (CF) patients experience pulmonary exacerbations and the three-minute step test (3-min step test) may be a simple and easy-to-perform functional test to help identify such episodes. The present study aimed to evaluate the association of the 3-min step test with the occurrence of pulmonary exacerbations in children with CF., Methods: Cross-sectional study of CF patients aged 6 years and older. Pulmonary exacerbations were assessed using both the Fuchs criteria and the Kanga Score. The 3-min step test was performed using a 15 cm-high step and heart rate (HR), oxygen saturation (SpO2), and dyspnea were measured before and after the test. Correlations between the test and the scores, as well as comparisons between patients experiencing or not an exacerbation, were performed., Results: Sixty-two patients (11.1±4.3 years) were included. Both the Fuchs criteria and the Kanga score correlated significantly with age, forced expiratory volume in the first second (FEV1), final SpO2, and 1-min recovery SpO2. A fall greater than 4% in the final SpO2 was significantly associated with the presence of a pulmonary exacerbation, considering both Fuchs and Kanga criteria. Age, resting HR, and HR after 1-min recovery were significantly higher, while FEV1, SpO2 at rest, final SpO2, and SpO2 after 1-min recovery were significantly lower in patients classified as exacerbated., Conclusions: Physiological responses to the 3-min step test are associated with the occurrence of pulmonary exacerbation in children with CF. Desaturation at the end of the test or during 1-min recovery may be the best variable to monitor.